These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38558281)

  • 1. Poorly controlled pediatric type 1 diabetes mellitus is a risk factor for metabolic dysfunction associated steatotic liver disease (MASLD): An observational study.
    Koutny F; Wiemann D; Eckert A; Meyhöfer S; Fritsch M; Pappa A; Wiegand S; Weyer M; Wurm M; Weghuber D; Holl RW
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1027-1037. PubMed ID: 38558281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
    Aernouts C; Beldé SPW; Lambrechts J; Mertens J; Ledeganck KJ; Francque SM; De Block CEM
    Diabetes Obes Metab; 2024 Sep; 26(9):3781-3790. PubMed ID: 38924290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.
    Song K; Seol EG; Yang H; Jeon S; Shin HJ; Chae HW; Kim EK; Kwon YJ; Lee JW
    Front Endocrinol (Lausanne); 2024; 15():1385002. PubMed ID: 38883602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alanine aminotransferase cutoffs for the pediatric fatty liver disease: Major impact of the reference population.
    Aitokari L; Lahti S; Kivelä L; Riekki H; Hiltunen P; Vuorela N; Viitasalo A; Soininen S; Huhtala H; Lakka T; Kurppa K
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):488-496. PubMed ID: 38314943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents.
    Wiegand S; Keller KM; Röbl M; L'Allemand D; Reinehr T; Widhalm K; Holl RW;
    Int J Obes (Lond); 2010 Oct; 34(10):1468-74. PubMed ID: 20531349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
    Al-Ozairi E; Irshad M; AlKandari J; Mashankar A; Alroudhan D; le Roux CW
    Diabetes Obes Metab; 2024 Sep; 26(9):4052-4059. PubMed ID: 38984381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children.
    Maxwell SL; Price JC; Perito ER; Rosenthal P; Wojcicki JM
    Pediatr Obes; 2024 Jun; 19(6):e13109. PubMed ID: 38453472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased liver echogenicity and liver enzymes are associated with extreme obesity, adolescent age and male gender: analysis from the German/Austrian/Swiss obesity registry APV.
    Greber-Platzer S; Thajer A; Bohn S; Brunert A; Boerner F; Siegfried W; Artlich A; Moeckel A; Waldecker-Krebs H; Pauer S; Holl RW;
    BMC Pediatr; 2019 Sep; 19(1):332. PubMed ID: 31514755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents.
    Graham RC; Burke A; Stettler N
    J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):442-9. PubMed ID: 19644391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five heterogeneous HbA1c trajectories from childhood to adulthood in youth with type 1 diabetes from three different continents: A group-based modeling approach.
    Clements MA; Schwandt A; Donaghue KC; Miller K; Lück U; Couper JJ; Foster N; Schröder C; Phelan H; Maahs D; Prinz N; Craig ME;
    Pediatr Diabetes; 2019 Nov; 20(7):920-931. PubMed ID: 31418521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT.
    Lee J; Byrne CJ; Brennan PN; MacPherson I; Dow E; Dillon JF
    Ann Hepatol; 2024; 29(2):101280. PubMed ID: 38219950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals.
    Liu CH; Chang YP; Fang YJ; Cheng PN; Chen CY; Kao WY; Lin CL; Yang SS; Shih YL; Peng CY; Tsai MC; Huang SC; Su TH; Tseng TC; Liu CJ; Chen PJ; Kao JH
    J Gastroenterol; 2024 Jul; 59(7):609-620. PubMed ID: 38613690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated steatotic liver disease and risk of esophageal cancer in patients with diabetes mellitus: a nationwide cohort study.
    Jeon YJ; Han K; Lee SW; Lee JE; Park J; Cho IY; Cho JH; Shin DW
    Dis Esophagus; 2024 Jul; 37(8):. PubMed ID: 38587429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms.
    Richter MM; Kemp IM; Heebøll S; Winther-Sørensen M; Kjeldsen SAS; Jensen NJ; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Madsbad S; Schiødt FV; Nørgaard K; Schmidt S; Gluud LL; Haugaard SB; Holst JJ; Nielsen S; Rungby J; Wewer Albrechtsen NJ
    Metabolism; 2024 Jul; 156():155915. PubMed ID: 38631460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.
    Sogabe M; Okahisa T; Kagawa M; Sei M; Ueda H; Yokoyama R; Kagemoto K; Tanaka H; Kida Y; Nakamura F; Tomonari T; Okamoto K; Kawano Y; Miyamoto H; Sato Y; Nakasono M; Takayama T
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1107-1114. PubMed ID: 38419514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Choi E; Ramirez Tovar A; He Z; Soler Rodriguez DM; Vos MB; Arora S; Fadoju D
    Children (Basel); 2024 Feb; 11(3):. PubMed ID: 38539310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
    Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
    Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.